Weill Cornell Medical College, Cornell University
`Faculty Curriculum Vitae
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Name: Szilárd Kiss, MD
`
`Signature:
`
`Date of Preparation: 8-November-2020
`
`
`A.
`
`
`PERSONAL DATA
`
`Office address:
`
`Office telephone:
`
`Home address:
`
`Cell phone:
`
`1305 York Ave, 11th Floor, New York, New York 10028
`
`646-962-2217
`
`333 E. 91st ST, Apt 15A, New York, New York 10128
`
`617-304-1691
`
`Email address - Work:
`
`szk7001@med.cornell.edu
`
`Email address - Personal:
`Is your eligibility to work in the U.S.
`based on an employment visa?:
`
`
`Szilard.Kiss@gmail.com
`
`No
`
`
`
`
`
`B.
`
`EDUCATION
`
`Academic Degree(s)
`
`
`Degree, include
`field of study
`BA, Biology,
`cum laude
`
`Institution name, city and state
`
`Columbia College, Columbia University,
`New York, New York
`
`Dates attended
`(mm/yyyy-mm/yyyy)
`
`08/1993 – 06/1997
`
`MD
`
`Columbia University Vagelos College of
`Physicians and Surgeons, New York, NY
`
`08/1997 – 06/2002
`
`Year Awarded
`
`1997
`
`2002
`
`
`
`C.
`
`Title
`
`POSTDOCTORAL TRAINING
`
`
`Institution, city and state
`
`Dates (mm/yy - mm/yy)
`
`Internal Medicine Internship
`
`Mount Sinai West and Mount Sinai
`Morningside Hospitals, New York, NY
`
`07/02 – 06/03
`
`November 2020
`
`
`
`1
`
`Regeneron Exhibit 1032.001
`
`

`

`Ophthalmology Residency
`
`Massachusetts Eye & Ear Infirmary,
`Harvard Medical School, Boston, MA
`
`Surgical Vitreo-Retina Fellowship
`
`Massachusetts Eye & Ear Infirmary,
`Harvard Medical School, Boston, MA
`
`Chief Fellow, Retina Service
`
`Massachusetts Eye & Ear Infirmary,
`Harvard Medical School, Boston, MA
`
`07/03 – 06/06
`
`07/06 – 06/08
`
`07/07 – 06/08
`
`PROFESSIONAL POSITIONS & EMPLOYMENT
`
`
`
`D.
`
`Academic Appointments
`
`
`Title
`
`Institution, city and state
`
`Dates (mm/yy - mm/yy)
`
`Instructor of Ophthalmology
`
`Massachusetts Eye & Ear Infirmary,
`Harvard Medical School, Boston, MA
`
`Assistant Professor of
`Ophthalmology
`
`Weill Cornell Medical College, Cornell
`University, New York, New York
`
`Director, Compliance
`
`Director, Clinical Research
`
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`
`07/06 – 06/08
`
`08/08 – 08/13
`
`08/09 – 07/20
`
`08/09 – 07/20
`
`Associate Professor of
`Ophthalmology
`
`Weill Cornell Medical College, Cornell
`University, New York, New York
`
`09/13 – Present
`
`Division Chief, Retina
`
`Director, Teleophthalmology
`
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`
`10/15 – Present
`
`07/17 – Present
`
`Associate Dean, Clinical
`Compliance
`
`Weill Cornell Medical College, Cornell
`University, New York, New York
`
`11/19 – Present
`
`Vice-Chair, Compliance
`
`Vice-Chair, Research
`
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`Department of Ophthalmology, Weill
`Cornell Medical College, Cornell
`University, New York, New York
`
`08/20 – Present
`
`08/20 – Present
`
`November 2020
`
`
`
`2
`
`Regeneron Exhibit 1032.002
`
`

`

`
`Hospital Appointments
`
`
`Title
`
`Clinical Associate, Surgery
`
`Institution, city and state
`
`Dates (mm/yy - mm/yy)
`
`Massachusetts General Hospital, Boston,
`Massachusetts
`
`07/06 – 06/08
`
`Associate Staff, Division of
`Ophthalmology
`
`Beth Israel/Deaconess Medical Center,
`Boston, Massachusetts
`
`07/06 – 06/08
`
`Assistant Attending
`
`Associate Attending
`
`New York–Presbyterian Hospital/Weill
`Cornell Medical Center, New York, NY
`
`08/08 – 08/13
`
`New York–Presbyterian Hospital/Weill
`Cornell Medical Center, New York, NY
`
`09/13 – Present
`
`Associate Attending Surgeon
`
`Memorial Sloan Kettering Cancer Center,
`New York, NY
`
`10/15 – Present
`
`LICENSURE, BOARD CERTIFICATION
`
`
`
`E.
`
`Licensure
`
`
`State
`
`New York
`
`
`
`DEA number:
`NPI number:
`
`
`
`Board Certification
`
`
`Number
`
`248096
`
`BK9692054
`1023076593
`
`
`Full Name of Board
`
`American Board of Ophthalmology
`
`Date of issue
`(mm/dd/yyyy)
`03/27/2008
`
`Date of last registration
`(mm/dd/yyyy) – (mm/dd/yyyy)
`01/01/2019 – 12/31/2021
`
`INSTITUTIONAL/HOSPITAL AFFILIATION
`
`
`
`F.
`
`
`Primary Hospital Affiliation:
`
`Other Hospital Affiliations:
`
`
`
`
`Certificate #
`(indicate if board eligible)
`28735
`
`Dates of Certification
`(mm/dd/yyyy) – (mm/dd/yyyy)
`10/28/2007 – 12/31/2027
`
`New York–Presbyterian Hospital/Weill Cornell Medical Center,
`New York, NY
`Memorial Sloan Kettering Cancer Center, New York, NY
`
`
`November 2020
`
`
`
`3
`
`Regeneron Exhibit 1032.003
`
`

`

`EMPLOYMENT STATUS
`
`
`G.
`
`Name of Current Employer(s): Weill Cornell Medical College
`Current Employment Status:
`Full-time salaried by Weill Cornell
`
`H.
`
`
`HONORS, AWARDS
`
`Name of award
`
`Student Scholarship in Cerebrovascular Disease
`Medical Student Research Scholarship in
`Geriatric Pharmacology
`Glorney-Raisbeck Medical Student Scholarship
`in Cardiovascular Research
`Dr. Alfred Steiner Dean's Award for Outstanding
`Medical Student Research
`
`Ophthalmology Fellow Merit Award
`Sanford D. Hecht Award for Outstanding
`Research
`Ronald G. Michels Foundation Fellowship Award
`
`Paul Kayser International Scholar Award
`
`Rhett Buckler Award, Retina Congress Film
`Festival
`Honor Award
`
`RBP Physician-Scientist Award
`
`Honor Award
`
`New York Rising Star
`Power List Top 40 Under 40 Ophthalmologist
`World-Wide
`Senior Honor Award
`
`New York Super Doctor
`
`Organization
`American Heart
`Association
`Merck/AFAR
`New York Academy of
`Medicine
`Columbia University
`Vagelos College of
`Physicians and Surgeons
`The Heed Ophthalmic
`Foundation
`New England
`Ophthalmological Society
`The Ronald G. Michels
`Fellowship Foundation
`Pan American
`Association of
`Ophthalmology
`American Society of
`Retina Specialists
`American Society of
`Retina Specialists
`Research to Prevent
`Blindness
`American Academy of
`Ophthalmology
`Super Doctors
`
`The Ophthalmologist
`American Society of
`Retina Specialists
`
`Super Doctors
`
`Date Awarded
`(yyyy)
`2000
`
`2000
`
`2000
`
`2000
`
`2006, 2007
`
`2007
`
`2007
`
`2008
`
`2009
`
`2013
`
`2013
`
`2014
`
`2014, 2015
`
`2015
`
`2016
`2016, 2017,
`2018, 2019,
`2020
`
`November 2020
`
`
`
`4
`
`Regeneron Exhibit 1032.004
`
`

`

`Top Doctors New York Metro Area
`
`Castle Connolly
`
`Retina 150 Innovators in Medical and Surgical
`Retina
`Charter Inductee, Retina Hall of Fame
`Journal of VitreoRetinal Diseases Master
`Contributor Award
`
`Ocular Surgery News
`
`Retina Hall of Fame
`American Society of
`Retina Specialists
`
`2016, 2017,
`2018, 2019,
`2020
`2016
`
`2017
`
`2020
`
`
`I.
`
`
`PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS
`
`Organization
`American Academy of Ophthalmology
`(AAO)
`Association for Research in Vision
`and Ophthalmology (ARVO)
`American Society of Retina
`Specialists (ASRS)
`Society of Heed Fellows, elected
`member
`Pan-American Association of
`Ophthalmology
`Manhattan Retina Club
`
`Vitrectomy-Buckle Society
`The Ophthalmic Laser Surgical
`Society, elected member
`The New York Clinical Society,
`elected member
`Retina CONNECT
`European Society of Retina
`Specialists
`American Society of Gene & Cell
`Therapy
`Macula Society, elected member
`
`Date (yyyy-yyyy)
`
`2003 – present
`
`2003 – present
`
`2006 – present
`
`2006 – present
`
`2007 – present
`
`2008 – present
`
`2009 – present
`
`2009 – present
`
`2010 – present
`
`2010 – present
`
`2010 – present
`
`2011 – present
`
`2012 – present
`
`Retina Society, elected member
`
`2012 – present
`
`Club Jules Gonin, elected member
`
`2014 – present
`
`
`
`
`November 2020
`
`
`
`5
`
`Regeneron Exhibit 1032.005
`
`

`

`PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES
`
`J.
`
`
`Weill Cornell Activity (Current or
`Anticipated)
`Teaching
`Clinical
`Administrative
`Research
`Total
`
`Percent Effort (%)
`10%
`50%
`30%
`10%
`100%
`
`Does the activity involve Weill Cornell
`students/research trainees? (Yes/No)
`Yes
`Yes
`No
`Yes
`
`
`EDUCATIONAL CONTRIBUTIONS
`
`
`
`K.
`
`Teaching
`
`Didactic teaching
`
`2008 – Present
`
`
`2008 – Present
`
`
`2009 – Present
`
`
`Clinical teaching
`
`2008 – Present
`
`Ophthalmology Lecture Series, Department of Ophthalmology, Weill Cornell
`Medical College, New York, New York; Medical and surgical retina related
`didactic curriculum; Topics covered include – Diagnosis, Treatment and
`Follow-up of Diabetic Retinopathy; Diagnosis, Treatment and Follow-up of
`Age-Related Macular Degeneration; Diagnosis, Treatment and Follow-up of
`Retinal Vein Occlusion; Retinal Electrophysiology; Retinal Degenerations;
`Use of Optical Coherence Tomography, Fluorescein Angiography,
`Indocyanine Green Angiography and Fundus Autofluorescence Imaging for
`the Diagnosis, Treatment and Follow-up of Various Retinal Disorders.
`Approximately 5 lectures throughout academic year, each 60 minutes in
`duration for medical students, residents and fellows.
`
`Vitreo-Retinal Journal Club, Department of Ophthalmology, Weill Cornell
`Medical College, New York, New York; Comprehensive review of recent
`literature and interesting surgical and medical retina cases with residents,
`fellows and attendings on the retina serice. Approximately 10 meetings
`throughout academic year, each 90 minutes in duration.
`
`Clinic Compliance Lectures, Department of Ophthalmology, Weill Cornell
`Medical College, New York, New York; Approximately 3 to 5 lectures
`delivered throughout academic year, each 60 minutes in duration, for
`residents, fellows and ophthalmology attending physicians on matters related
`to supervision, documentation, billing and clinical compliance topics.
`
`Ophthalmology/Retina Clinical Preceptorship, Department of Ophthalmology,
`Weill Cornell Medical College, New York, New York; Teaching and
`supervisory role for a second-year Weill Cornell ophthalmology resident
`(PGY-3) and 1 or 2 Weill Cornell vitreo-retinal fellows (PGY-5 or PGY-6),
`assigned to 3-half day clinics; after examining patients, determining the
`
`November 2020
`
`
`
`6
`
`Regeneron Exhibit 1032.006
`
`

`

`
`2008 – Present
`
`
`2009 – Present
`
`diagnosis, and formulating a treatment plan, trainees present the patient,
`whom we then examine together; feedback and teaching occur during each
`patient encounter and at a more formalized chart review at the conclusion of
`each clinic. Medical students from Weill Cornell and other national and
`international universities are often present in my clinics as are international
`non-clinical fellows.
`
`Ophthalmology/Retina Surgical Preceptorship, Department of
`Ophthalmology, Weill Cornell Medical College, New York, New York;
`Teaching and supervisory role for a Weill Cornell vitreo-retinal fellow (PGY-5
`or PGY-6), assigned to all my surgical cases during one day of surgery;
`depending the trainee’s level and the complexity of the case, the fellow will
`either serve as an assistant or as a primary surgeon for the case; feedback
`and teaching occur prior to the case on formulation of a surgical plan, during
`the case itself and after the completion of the operation in more formalized
`and systematic manner. Medical students from Weill Cornell and other
`national and international universities, Weill Cornell ophthalmology residents,
`and international non-clinical fellows are often present during my surgical
`cases. Depending on skill and level of interest in further specializing in retina,
`Weill Cornell ophthalmology residents also assist in the surgical procedures
`under my direct supervision.
`
`Clinic Compliance Lectures, Department of Ophthalmology, Weill Cornell
`Medical College, New York, New York; Approximately 3 to 5 lectures
`delivered throughout academic year, each 60 minutes in duration, for
`residents, fellows and ophthalmology attending physicians on matters related
`to supervision, documentation, billing and clinical compliance topics.
`
`
`Continuing education and professional education
`
`Title
`Advanced Retinal Visualization With
`High Resolution Optical Coherence
`Tomography
`
`Institution/Location
`Invited Faculty, OSN New York, 2010
`Ophthalmology Update, New York, New
`York
`
`The Future of Retinal-Drug Technology:
`Sustained Delivery Systems
`
`Faculty, Vancouver, British Columbia,
`Canada
`
`Weill Cornell Keratoprosthesis Course:
`Advancements in Visual Rehabilitation
`
`Course Co-Director and Faculty, New York,
`New York
`
`Diabetic Macular Edema:
`Pathophysiology and Evolving
`Treatment Strategies
`
`Symposia Chair and Guest Faculty, OSN
`New York, 2011 Ophthalmology Update,
`New York, New York
`
`Advances in the Treatment of Retinal
`Vein Occlusion and Uveitis
`
`Faculty, St. Louis, Missouri
`
`November 2020
`
`
`
`Dates (yyyy)
`
`2010
`
`2010
`
`2010
`
`2011
`
`2011
`
`7
`
`Regeneron Exhibit 1032.007
`
`

`

`Advances in the Treatment of Retinal
`Vein Occlusion and Uveitis
`
`Evaluating and Integrating Innovative
`Therapies in the Treatment of Macular
`Edema Secondary to Diabetic
`Retinopathy and Retinal Vein Occlusion
`
`Evaluating and Integrating Innovative
`Therapies in the Treatment of Macular
`Edema Secondary to Diabetic
`Retinopathy and Retinal Vein Occlusion
`
`Evaluating and Integrating Innovative
`Therapies in the Treatment of Macular
`Edema Secondary to Diabetic
`Retinopathy and Retinal Vein Occlusion
`
`New Developments in the
`Pharmacotherapy of Wet Macular
`Degeneration
`
`New Developments in the
`Pharmacotherapy of Wet Macular
`Degeneration
`
`An Evolving Standard of Care:
`Emerging Treatment Options for Retinal
`Vascular Disease
`
`Faculty, Philadelphia, Pennsylvania
`
`2011
`
`Program Chair and Faculty, University of
`Virginia Department of Ophthalmology,
`Charlottesville, Virginia
`
`Program Chair and Faculty, Albany Medical
`Center, Lions Eye Institute, Slingerlands,
`New York
`
`Program Chair and Faculty, Bronx-Lebanon
`Hospital Center, Bronx, New York
`
`2011
`
`2011
`
`2011
`
`Faculty, New York, New York
`
`2012
`
`Faculty, Boston, Massachusetts
`
`2012
`
`Faculty, New York, New York
`
`2012
`
`Applying New Data to Improve Standard
`of Care in Retinal Disease
`
`Moderator/Faculty, Raleigh-Durham, North
`Carolina
`
`New Developments in the
`Pharmacotherapy of Wet Macular
`Degeneration
`
`Faculty, Washington, DC
`
`2012
`
`2012
`
`Applying New Data to Improve Standard
`of Care in Retinal Disease
`
`Moderator, Boston, Massachusetts
`
`2012
`
`New Developments in Retinal
`Pharmacotherapy 2013
`
`Faculty, New York, New York
`
`2013
`
`November 2020
`
`
`
`8
`
`Regeneron Exhibit 1032.008
`
`

`

`Contemporary Management of
`Diseases of the Vitreomacular Interface
`
`Program Chair and Faculty, Kiawah Island,
`South Carolina
`
`Retina in Review: State of the Science
`in Treating Retinal Vein Occlusion
`
`Program Chair and Faculty, American
`Society of Retina Specialists Annual
`Meeting, Toronto, Canada
`
`2013
`
`2013
`
`Anti-VEGF Agents in Wet AMD:
`Confounding the Consensus
`
`Faculty, New York, New York
`
`2013
`
`Confronting Uveitis and Postoperative
`Inflammation: Challenges in Diagnosis
`and Treatment
`
`Faculty, 2013 Annual Meeting of the
`American Academy of Ophthalmology, New
`Orleans, LA
`
`Intravitreal Steroids – Balancing
`Effective Use with Intraocular Pressure
`Control
`
`Faculty, Steroid Devices in Retinal Disease:
`A Paradigm Shift in Combination Therapy,
`Boston, MA
`
`Clinical Management of the Diabetic
`Patient in the New Healthcare Model –
`Integration of Ultra Widefield Imaging
`
`The Exchange 2014, Vision Source's North
`American Meeting, Boston, MA
`
`What’s New in the Treatment of Retinal
`Vein Occlusion
`
`Faculty, Frontiers of Medical Retina 2014:
`Clinical Decision Making in Retinal
`Pharmacotherapy, Detroit, MI
`
`Advances in Age-Related Macular
`Degeneration
`
`Course Chair and Faculty, Advances in Age-
`Related Macular Degeneration, New York,
`NY
`
`Strategies and Options in Managing
`Wet and Dry Age-Related Macular
`Degeneration
`
`Course Chair and Faculty, Strategies and
`Options in Managing Wet and Dry Age-
`Related Macular Degeneration, San Diego,
`CA
`
`2013
`
`2014
`
`2014
`
`2014
`
`2014
`
`2014
`
`Diabetic Eye Disease: Evolving
`Treatment Paradigms
`
`Planning Committee Member, Diabetic Eye
`Disease: Evolving Treatment Paradigms
`
`2014 – 2015
`
`November 2020
`
`
`
`9
`
`Regeneron Exhibit 1032.009
`
`

`

`The Role for Enhanced Imaging in
`Diagnosing, Monitoring, and Treating
`Diabetic Eye Disease
`
`Faculty, Diabetic Eye Disease: Implications
`of Early Recognition, Treatment, and
`Continuity of Care Chicago, IL
`
`Real World Use of Anti-VEGF Therapy:
`Clinical Experience beyond Pivotal
`Trials
`
`Course Chair and Faculty, Rapid Response:
`Real World Use of Anti-VEGF Therapy:
`Clinical Experience beyond Pivotal Trials,
`Chicago, IL
`
`Treatment Strategies and Outcomes for
`Patients with Diabetic Macular Edema
`
`Faculty, Treatment Strategies and
`Outcomes for Patients with Diabetic Macular
`Edema, Chicago, IL
`
`Managing Diabetic Eye Disease:
`Advances in Treatment
`
`Challenges in the Diagnosis, Detection
`and Follow-up Treatment of Diabetic
`Retinal Disease
`
`Findings from DRCR.net Protocols I and
`T and Other Trials
`
`Synthesizing Traditional and Novel
`Options for Management of DR: Case-
`Based Approach
`
`Artificial Intelligence and Diabetic
`Retinopathy Screening
`
`Course Chair and Faculty, The Diabetic Eye:
`Role of the Ophthalmologist in Screening,
`Management, and Prevention, New York,
`NY
`
`Faculty, Clarifying the Role of Novel and
`Emerging Treatments For Diabetic
`Retinopathy and Related Eye Disorders, Las
`Vegas, NV
`
`Faculty, Clarifying the Role of Novel and
`Emerging Treatments For Diabetic
`Retinopathy and Related Eye Disorders, Las
`Vegas, NV
`
`Faculty, Clarifying the Role of Novel and
`Emerging Treatments For Diabetic
`Retinopathy and Related Eye Disorders, Las
`Vegas, NV
`
`Faculty, OSN New York: RETINA 2020, New
`York, New York
`(delivered virtually)
`
`Diabetic Retinopathy and Diabetic
`Macular Edema
`
`Faculty/Discussant, OSN New York:
`RETINA 2020, New York, New York
`(delivered virtually)
`
`Comparison of Widefield Imaging
`Devices and How They Have Impacted
`Practice
`
`Faculty, OSN New York: RETINA 2020, New
`York, New York
`(delivered virtually)
`
`2014
`
`2014
`
`2014
`
`2014
`
`2015
`
`2015
`
`2015
`
`2020
`
`2020
`
`2020
`
`November 2020
`
`
`
`10
`
`Regeneron Exhibit 1032.010
`
`

`

`Ultra Widefield Optical Coherence
`Tomography for Evaluating the
`Peripheral Retina: Case Presentation
`
`Faculty, OSN New York: RETINA 2020, New
`York, New York
`(delivered virtually)
`
`2020
`
`
`Community education or patient outreach
`
`Television Appearances Related to 3D Visualization of the Retina:
`
`
`1. Weill Cornell 3D CAVE™ - CBS Special –
`https://www.youtube.com/watch?v=_5wdU5M3Daw
`
`
`
`2. Touring the Body in 3-D – Fox News Special – https://www.foxnews.com/health/touring-
`the-body-in-3-d
`
`CLINICAL PRACTICE, INNOVATION, and LEADERSHIP
`
`
`
`L.
`
`Clinical Practice
`
`2008 – Present
`
`Ophthalmology/Retina Ambulatory Practice, Department of Ophthalmology,
`Weill Cornell Medical College, New York, New York; Outpatient evaluation
`and management of adult and pediatric patients with complex vitreo-retinal
`pathologies (including age-related macular degeneration, diabetic
`retinopathy, retinal vascular disorders, inherited retinal degenerations,
`infectious and non-infectious uveitis, and inherited and acquired
`maculopathies); oftentimes patients are referred from retina specialists in the
`community or come for a second or third opinion from around the country
`and around the world; initially starting out at 4 full days per week and more
`recently decreasing to three ½ days per week with my increasing research
`and administrative responsibilities.
`
`Ophthalmology/Retina Surgical Practice, Department of Ophthalmology,
`Weill Cornell Medical College, New York, New York; Surgical management of
`adult patients with complex vitreo-retinal pathologies (including
`rhegmatogenous and tractional retinal detachments, giant retinal tears,
`proliferative vitreoretinopathy, macular hole, macular pucker, vitreous
`hemorrhage, proliferative diabetic retinopathy, retina surgery in patients with
`permanent keratoprosthesis); oftentimes patients are referred in from retina
`specialists in the community or come for a second or third opinion from
`around the country and around the world. One day per week.
`
`Ophthalmology/Retina Inpatient/Consult Attending, Department of
`Ophthalmology, Weill Cornell Medical College, New York, New York; Serve
`as the primary inpatient attending evaluating and treating patients admitted to
`New York-Presbyterian Hospital with a variety of ophthalmic and retinal
`disorders. Directly supervise and teach the Weill Cornell ophthalmology
`consult resident (PGY-3) and Weill Cornell consult retinal fellow (PGY-5 or
`
`
`2008 – Present
`
`
`2008 – Present
`
`November 2020
`
`
`
`11
`
`Regeneron Exhibit 1032.011
`
`

`

`PGY-6) Two weeks per year for comprehensive ophthalmology consult
`service and 6 weeks per year for retina consult service.
`
`
`
`Clinical Innovations
`
`
`
`
`
`
`
`
`
`
`1. Development and implementation of ultra widefield retinal imaging for the diagnosis,
`classification and follow-up of patients with retinal disorders.
`
`Since 2008, I was among the first retina specialists to recognize and to characterize the
`clinical applicability of ultra widefield (UWF) retinal photography, fluorescein angiography,
`indocyanine green angiography, autofluorescence and optical coherence tomography in
`the diagnosis, staging, treatment and follow-up of a variety retinal disorders. Innovative
`insights on imaging the retina has revolutionized the understanding of such disorders as
`diabetic eye disease and it has changed the standard imaging of patients away from
`traditional methods to UWF imaging utilized throughout the world. This work on UWF
`imaging in diabetic retinopathy was directly responsible for an on ongoing, large,
`prospective multicenter, clinical trial that will likely result in a brand-new classification
`system for diabetic retinopathy, a classification system that has been in place since the
`1970’s.
`
`2. Development of a novel cell-based therapy for ocular cytomegalovirus infection.
`
`Working with collaborators at Memorial-Sloan Kettering Cancer Center, in 2009, I was the
`first to propose and then to help development cell-based immunotherapy for the treatment
`of infectious posterior uveitis, including multidrug resistant CMV retinitis. It is the first such
`application for any ocular disorder. Prospective international clinical trials that also include
`ophthalmic manifestations of CMV are ongoing. Patients from around the world are being
`referred to MSKCC and WCM to receive this therapy on and off ongoing protocols.
`
`3. Pioneering surgical techniques and instrumentation for innovative approaches to complex
`vitreoretinal pathologies.
`
`In 2006, my colleagues and I were one of the first to recognize the advantages for small-
`gauge vitrectomy over the conventional sutured techniques. We then established a
`sutureless approach to retina surgery with permanent keratoprosthesis, a procedure which
`is now the standard in the field world-wide. More recently, in line with my gene therapy
`work outlined above, I have been developing surgical tools, techniques and virtual-reality
`training modules for the delivery of gene therapy vectors to ocular various structures. As a
`result of these innovations, I serve as the primary surgical trainer and surgical reviewer for
`several ongoing surgical trials.
`
`4. Development of Weill Cornell Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
`Ophthalmic Severity Scale
`
`My observations of patients with LINCL, starting in 2009, led to the first characterization of
`the ocular manifestations of this patient population. Based on these observations, I
`developed and validated a five step Weill Cornell LINCL Ophthalmic Severity Scale and
`showed that the ophthalmic signs of LINCL correlate closely with the degree of
`
`November 2020
`
`
`
`12
`
`Regeneron Exhibit 1032.012
`
`

`

`neurological dysfunction and advancing age in these patients. The Weill Cornell LINCL
`Ophthalmic Severity Scale has become the standard worldwide for evaluating LINCL
`patients, both clinically and in several ongoing clinical trials.
`
`5. Implementation of a teleophthalmology screening program in Primary Care and
`Endocrinology Clinics at Weill Cornell Medicine.
`
`Even prior to the current COVID-19 pandemic, in collaboration with the Primary Care and
`Endocrine physician groups, we realized the importance of improving on the screening for
`potentially blinding ocular effects of diabetes. In 2018, after careful consideration of
`patient populations and clinical needs, I placed five ultra widefield retinal imaging devices
`into Primary Care and Endocrinology clinics. An annual fundus photo has now become a
`routine part of a diabetic patient evaluation in these settings. Since the launch of the
`teleophthalmology initiative, nearly 1,000 patients have undergone teleophthalmology
`imaging. Of those requiring follow-up evaluation in the ophthalmology clinic, there is over
`95% compliance rate, in direct contrast to the approximately 20% rate noted previously
`when no devices where implemented.
`
`
`
`Clinical Leadership
`
`
`Leadership Role
`
`Description
`
`Director, Compliance, Department
`of Ophthalmology, Weill Cornell
`Medical College
`
`Oversee all aspects of clinical and
`research compliance related matters for
`the Ophthalmology Department.
`
`Director, Clinical Research,
`Department of Ophthalmology,
`Weill Cornell Medical College
`
`Division Chief, Retina, Department
`of Ophthalmology, Weill Cornell
`Medical College
`
`Director, Teleophthalmology,
`Department of Ophthalmology,
`Weill Cornell Medical College
`
`Introduced a clinical trials program, both
`sponsored and investigator initiated
`clinical research, in the Ophthalmology
`Department; manage both internal and
`external clinical trial efforts.
`
`Direct a regionally, nationally and
`internationally recognized Retina Service
`that cares for some of the most complex
`medical and surgical patients in addition
`to teaching medical students and
`residents as well as training 2-4 retina
`fellows yearly; the service is has the most
`robust translational and clinical research
`program within the department.
`
`As the inaugural director, introduced
`remote retinal screening of diabetic
`patients; oversee an ever-expanding
`departmental telehealth initiative that now
`includes Retina, Cornea, Glaucoma,
`Oculoplastics and Neuro-Ophthalmology
`Services within the department.
`
`Dates
`
`2009 – 2020
`
`2009 – 2020
`
`2015 – Present
`
`2017 – Present
`
`November 2020
`
`
`
`13
`
`Regeneron Exhibit 1032.013
`
`

`

`Associate Dean, Clinical
`Compliance, Weill Cornell Medical
`College
`
`Chair, General Faculty Council,
`Weill Cornell Medical College
`
`In collaboration with the Cornell University
`Auditor and Chief Audit Executive,
`oversee aspects of Clinical Compliance at
`Weill Cornell Medical College.
`
`Elected by fellow Weill Cornell Medical
`College Faculty to lead the administrative
`body responsible for considering all
`matters of interest and concern to the
`clinical and research faculty.
`
`2019 – Present
`
`2019 – Present
`
`Vice-Chair, Compliance,
`Department of Ophthalmology,
`Weill Cornell Medical College
`
`Oversee all aspects of clinical and
`research compliance related matters for
`the Ophthalmology Department.
`
`2020 – Present
`
`Vice-Chair, Research, Department
`of Ophthalmology, Weill Cornell
`Medical College
`
`In consultation with the Director of the
`Ophthalmology Dyson Research Institute,
`manage basic science, translational and
`clinical research efforts related to the
`department, including external and
`institutional collaborations.
`
`2020 – Present
`
`RESEARCH
`
`
`
`M.
`
`Research Activities:
`
`Currently, my clinical and translational research efforts have focused on four broad areas: ocular gene and
`cellular therapy, novel therapeutic targets for ocular neovascularization, complex vitreoretinal surgical
`techniques, and retinal imaging.
`
`Key Scientific contributions:
`1. For over 15 years, I have been working on the development of novel sustained delivery
`approaches, most notably gene therapy, for the long-term treatment of pathological ocular
`neovascularization associated with diabetic retinopathy, age-related macular degeneration
`and inherited retinal disorder. Several of the gene therapy vectors and surgical
`approaches that I was instrumental in developing and testing in preclinical primate and
`mouse models have entered and will continue to enter human clinical trials.
`
`
`2. I was among the first retina specialists to recognize and to characterize the clinical utility of
`ultra-widefield fundus photography, fluorescein angiography, indocyanine green
`angiography, and autofluorescence in the diagnosis and follow-up of a variety retinal
`disorders. Our work in diabetic retinopathy was in part responsible for an on ongoing
`prospective multicenter clinical trial that may result in a new classification system for
`diabetic retinopathy using ultra widefield imaging.
`
`3. I was among the first retina specialists to examine the ‘real-world’ utilization and ‘real-
`world’ visual outcomes of pharmacotherapies for a variety of retinal disorders including
`age-related macular degeneration, retinal vein occlusion and diabetic retinopathy.
`Although we set our patients’ expectations based on the results of prospective clinical
`
`November 2020
`
`
`
`14
`
`
`
`Regeneron Exhibit 1032.014
`
`

`

`trials, our work showed that outside of those trials, patients are followed and treated much
`less frequently and, as a result, their visual outcomes may not match that of the clinical
`trials.
`
`
`4. I was the first to systematically describe and characterize of the ocular manifestations, the
`progression of retinal degeneration, and the response to gene therapy in patients with late
`infantile neuronal ceroid lipofuscinosis (LINCL, Batten disease). In the setting of
`prospective NIH funded phase 2 clinical trials here at Weill Cornell, I developed and
`validated a five step Weill Cornell LINCL Ophthalmic Severity Scale (PMID: 24015292). I
`showed that the ophthalmic signs of LINCL correlate closely with the degree of
`neurological dysfunction and advancing age in these patients. Weill Cornell LINCL
`Ophthalmic Severity Scale is now the standard for ophthalmic evaluation
`
`
`5. Harvesting the power of the immune system has revolutionized the treatment of numerous
`malignancies. Working with my collaborators at Memorial-Sloan Kettering Cancer Center,
`I was the first to development cell based/immune therapy for the treatment of infectious
`posterior uveitis, including multidrug resistant CMV retinitis. It is the first such application
`for any ocular disorder and has resulted in the filing of a patent. Prospective international
`clinical trials that also include ophthalmic manifestations of CMV are ongoing.
`
`
`6. For over a decade, I have been developing novel surgical techniques and instrumentation
`for innovative approaches to complex vitreoretinal pathologies. I was one of the first to
`recognize the advantages for small-gauge vitrectomy over the conventional sutured
`techniques. I then established a sutureless approach to retina surgery with permanent
`keratoprosthesis, a procedure which is now the standard in the field. More recently, I’ve
`been developing surgical tools, techniques and virtual-reality training modules for the
`delivery of gene therapy vectors to ocular structures.
`
`
`
`Research Support:
`
`Current Research Funding
`
`
`1. 5UG1EY014231-19 (Glassman, PI); Diabetic Retinopathy Clinical Research Network; Role: Sub-
`Award
`
`
`Past (Completed) Funding
`
`
`
`
`1. W81XWH-14-1-0507 (Hajjar, PI); Department of Defense; Annexin A2 in Proliferative
`Vitreoretinopathy; Role: Co-Investigator
`
`2. RPB Physician-Scientist Award; Research to Prevent Blindness; Gene Therapy for the Treatment
`of Age-Related Macular Degeneration; Role: Principal-Investigator
`
`3. 5R01NS061848 / NINDS (Ronald, C, PI): Gene Therapy for Batten Disease Using AAVrh.10
`Expressing Human CLN2 cDNA; Role: Collaborator
`
`4. 1R21EY022165 (Boulan, PI) Cyclodextrins as Potential Treatment for Age-Related Macular
`Degeneration; Role: Co-Investigator
`
`
`November 2020
`
`
`
`15
`
`Regeneron Exhibit 1032.015
`
`

`

`5. UL1TR000457 (Nociari, PI) Cyclodextrins for the Treatment of Age-Related Macular Degeneration;
`Role: Collaborator
`
`6. UL1TR000457 (Rosenblatt/Pena, PI) Developing microRNA Therapeutics for Diabetic Retinopathy;
`Role: Collaborator
`
`7. Bill and Melinda Gates Foundation (Nussenzweig PI) Safety, pharmacokinetics and antiretroviral
`effects of two human anti-HIV monoclonal antibodies, alone and in combina